Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
21 9월 2023 - 9:00PM
Business Wire
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company
dedicated to addressing the underlying cause of severe diseases by
upregulating protein expression with RNA-based medicines, today
announced that management will participate in a panel presentation
at the 2023 Cantor Global Healthcare Conference on Tuesday,
September 26, 2023, at 9:55 a.m. ET.
A live webcast of the presentation will be available on the
Investors & News section of Stoke’s website at
https://investor.stoketherapeutics.com/ and can be accessed by
following this Link. A replay of the webcast will be available for
30 days following the presentation.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company
dedicated to addressing the underlying cause of severe diseases by
upregulating protein expression with RNA-based medicines. Using
Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene
Output) approach, Stoke is developing antisense oligonucleotides
(ASOs) to selectively restore protein levels. Stoke’s first
compound, STK-001, is in clinical testing for the treatment of
Dravet syndrome, a severe and progressive genetic epilepsy. Dravet
syndrome is one of many diseases caused by a haploinsufficiency, in
which a loss of ~50% of normal protein levels leads to disease.
Stoke is pursuing the development of STK-002 for the treatment of
autosomal dominant optic atrophy (ADOA), the most common inherited
optic nerve disorder. Stoke’s initial focus is haploinsufficiencies
and diseases of the central nervous system and the eye, although
proof of concept has been demonstrated in other organs, tissues,
and systems, supporting its belief in the broad potential for its
proprietary approach. Stoke is headquartered in Bedford,
Massachusetts with offices in Cambridge, Massachusetts. For more
information, visit https://www.stoketherapeutics.com/ or follow
Stoke on X @StokeTx.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230921541026/en/
Stoke Investor Contact: Eric Rojas Vice President,
Investor Relations IR@stoketherapeutics.com 617-312-2754
Stoke Therapeutics (NASDAQ:STOK)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Stoke Therapeutics (NASDAQ:STOK)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024